AU9640698A - Pharmaceutical combination of a cyclooxigenase-2 inhibitor and acetaminophen or an opiate - Google Patents

Pharmaceutical combination of a cyclooxigenase-2 inhibitor and acetaminophen or an opiate

Info

Publication number
AU9640698A
AU9640698A AU96406/98A AU9640698A AU9640698A AU 9640698 A AU9640698 A AU 9640698A AU 96406/98 A AU96406/98 A AU 96406/98A AU 9640698 A AU9640698 A AU 9640698A AU 9640698 A AU9640698 A AU 9640698A
Authority
AU
Australia
Prior art keywords
cyclooxigenase
opiate
acetaminophen
inhibitor
pharmaceutical combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU96406/98A
Inventor
Francois Camborde
Alix Cloarec
Eric Nicolai
Jean-Marie Teulon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UPSA SAS
Original Assignee
UNION PHARMA SCIENT APPL
UPSA SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNION PHARMA SCIENT APPL, UPSA SAS filed Critical UNION PHARMA SCIENT APPL
Publication of AU9640698A publication Critical patent/AU9640698A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU96406/98A 1997-10-27 1998-10-19 Pharmaceutical combination of a cyclooxigenase-2 inhibitor and acetaminophen or an opiate Abandoned AU9640698A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9713426 1997-10-27
FR9713426A FR2770131A1 (en) 1997-10-27 1997-10-27 Analgesic combinations of a cyclooxygenase-2 inhibitor and acetaminophen or an opiate having synergistic activity
PCT/IB1998/001789 WO1999021585A1 (en) 1997-10-27 1998-10-19 Pharmaceutical combination of a cyclooxigenase-2 inhibitor and acetaminophen or an opiate

Publications (1)

Publication Number Publication Date
AU9640698A true AU9640698A (en) 1999-05-17

Family

ID=9512671

Family Applications (1)

Application Number Title Priority Date Filing Date
AU96406/98A Abandoned AU9640698A (en) 1997-10-27 1998-10-19 Pharmaceutical combination of a cyclooxigenase-2 inhibitor and acetaminophen or an opiate

Country Status (3)

Country Link
AU (1) AU9640698A (en)
FR (1) FR2770131A1 (en)
WO (1) WO1999021585A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180651B1 (en) * 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
WO2000029022A1 (en) * 1998-11-12 2000-05-25 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with centrally acting analgesics
US6924303B2 (en) 2000-06-13 2005-08-02 Wyeth Analgesic and anti-inflammatory compositions containing COX-2 inhibitors
US8680081B2 (en) 2000-08-29 2014-03-25 Peter Van Patten Prophylactic treatment of migraine
AR038957A1 (en) 2001-08-15 2005-02-02 Pharmacia Corp COMBINATION THERAPY FOR CANCER TREATMENT
CA2476939C (en) * 2002-02-19 2012-08-28 Adcock Ingram Limited Pharmaceutical combinations of cox-2 inhibitors and opiates
GB0206505D0 (en) * 2002-03-19 2002-05-01 Euro Celtique Sa Pharmaceutical combination
AU2003249510A1 (en) * 2002-08-12 2004-02-25 Ranbaxy Laboratories Limited A parenteral dosage form of selective cox-2 inhibitors
US6864271B2 (en) * 2002-11-12 2005-03-08 The Foundation For The Lsu Health Sciences Center Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives
PL1534305T3 (en) 2003-05-07 2007-03-30 Osteologix As Treating cartilage / bone conditions with water-soluble strontium salts
CA3087729A1 (en) 2018-01-11 2019-07-18 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
CA2206978A1 (en) * 1994-12-21 1996-06-27 Merck Frosst Canada Inc. Diaryl-2-(5h)-furanones as cox-2 inhibitors
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
HUP9801602A3 (en) * 1995-04-04 1999-01-28 Glaxo Group Ltd Imidazo[1,2-a]pyridine derivatives, process for their production, pharmaceutical compositions and use thereof
US5691374A (en) * 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
UA57002C2 (en) * 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. (methylsulfonyl)phenyl-2-(5n)-furanon derivative, a pharmaceutical composition and a method for treatment

Also Published As

Publication number Publication date
WO1999021585A1 (en) 1999-05-06
FR2770131A1 (en) 1999-04-30

Similar Documents

Publication Publication Date Title
AU8140898A (en) Inhibitors of beta-lactamases and uses therefor
AU2805897A (en) Inhibitors of protein farnesyltransferase
IL118101A0 (en) Inhibitors of farnesyltransferase
AU4231197A (en) Hppd gene and inhibitors
AU1271297A (en) Inhibitor of ceramidase
AU6709596A (en) Amide compounds and use of the same
AU1618697A (en) Novel compounds and pharmaceutical use thereof
AU6034296A (en) Tricyclic inhibitors of protein farnesyltransferase
AU2845195A (en) Destruction of underwater objects
AU1616499A (en) Chemokine variants and methods of use
AU1117497A (en) Analgesic compounds and uses thereof
AU1665499A (en) Formulation of a combination comprised of opioid and alpha adrenergic agonistsand the application thereof
AU9640698A (en) Pharmaceutical combination of a cyclooxigenase-2 inhibitor and acetaminophen or an opiate
AU8662198A (en) Activated forms of notch and methods based thereon
AU9312598A (en) Inhibitors of collagen assembly
AU6303898A (en) Component of bromelain
AU2277597A (en) New inhibitors of sh2-mediated processes
AU6877998A (en) Dipeptide inhibitors of protein farnesyltransferase
AU6422298A (en) Pharmaceutical composition containing a phosphorylamide and an ayntibiotic
AU1287100A (en) Peptide inhibitor of browman-birk type
AU4641097A (en) New pharmaceutical parenteral formulation of a thrombin inhibitor
AU6118198A (en) Inhibitor of lymphocyte activation
AU8997498A (en) Tryptase inhibitor
AUPP076797A0 (en) Phospholipase inhibitor
AU2003204844A1 (en) Use of methylnaltrexone and related compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase